About Emendo Biotherapeutics
Emendo Biotherapeutics is a Healthcare company based in Ness Ziona (Israel) founded in 2015 by Shilo Ben Zeev, and was acquired by AnGes in December 2020. Re-designed gene-editing tools are developed for genetic disorders. Emendo Biotherapeutics has raised $61 million across 1 funding round from investors including AnGes and Takeda Ventures. Emendo Biotherapeutics offers products and services including CRISPR Platform and Custom Nucleases. Its focus areas include Life Sciences, Gene Therapy, DNA and dsDNA.
Company details
Emendo Biotherapeutics was founded in 2015 in Ness Ziona, Israel, within the biotechnology sector. Protein engineering technology is utilized to re-design genome editing tools, including CRISPR-associated protein 9 (Cas9), transcription activator-like effector nucleases (TALENs), and zinc finger nucleases (ZFNs). These modifications aim to enhance homology-directed repair (HDR), minimize non-homologous end joining (NHEJ), boost specificity, and lower off-target effects for treating genetic disorders.
- Headquarters Ness Ziona, Israel
- Founders Shilo Ben Zeev
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website emendobio.com
- Social LinkedIn
- Acquired by AnGes (Dec 2020)
Products & Services of Emendo Biotherapeutics
Emendo Biotherapeutics offers a comprehensive portfolio of products and services, including CRISPR Platform and Custom Nucleases.
Optimizes nucleases and guide-RNAs for targeted gene editing in diseases.
Develops customized editing solutions to minimize off-target effects.
Funding Insights of Emendo Biotherapeutics
Emendo Biotherapeutics has successfully raised a total of $61M through 1 strategic funding round. The most recent funding activity was a Series B round of $61 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $61M
- Total Rounds 1
- Last Round Series B — $61M
- First Round $61M
(Jan 2020)
- Investors Count 2
All 1 funding rounds of Emendo Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $61M | Series B | – | AnGes |
2 investors in total: 2 institutional.
Investors in Emendo Biotherapeutics
Emendo Biotherapeutics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include AnGes and Takeda Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| takedaventures.com | ||||
Gene-based therapies for rare diseases are developed by AnGes. | 1999 | anges.co.jp | Ibaraki, Japan |
Investor details for Emendo Biotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Emendo Biotherapeutics
28 people are tracked at Emendo Biotherapeutics (5 in leadership, 6 in board & advisors, 17 in team).
| Name | Role | Group |
|---|---|---|
Shilo Ben Zeev | Co-Founder | Leadership |
Smadar Hartuv | Director Of Quality Assurance | Leadership |
Noa Wertheimer | Director Scientific Strategy | Leadership |
Todd Wider | Chairman & Chief Medical Officer | Leadership |
Noa Oded Elkayam | Vp, Computational & Research | Leadership |
Harry Malech | Scientific Advisor | Board & advisors |
Andrew Kung | Scientific Advisor | Board & advisors |
Stephen H. Tsang | Scientific Advisor | Board & advisors |
Ei Yamada | Director | Board & advisors |
David Dale | Scientific Advisor | Board & advisors |
Naoya Satoh | Board Member | Board & advisors |
Ella Segal | EVP, Research & Development, Operations | Team |
Nelia Shechter | Expert | Team |
Bar Ayalon | Project Manager | Team |
Gil Freund | Devops And Cloud Architect | Team |
Noa Aloush | Senior Research Associate, Protein Development | Team |
Nadia Sinai | Senior Research Associate | Team |
Malki Aker | Senior Bioinformatics Scientist | Team |
Liat Zadikov | EVP, Human Resources | Team |
Michal Avidan Gartzman | EVP, Operations | Team |
8 more people are available in the full profile.
Complete people profiles for Emendo Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Emendo Biotherapeutics
3 dated milestones of Emendo Biotherapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Emendo Biotherapeutics is founded.
- Funding First funding round of $61.0M.
- Exit Acquired by AnGes.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Emendo Biotherapeutics
Complete news archive for Emendo Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emendo Biotherapeutics
Emendo Biotherapeutics was founded in 2015 and raised its 1st funding round 5 years after it was founded.
Emendo Biotherapeutics is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Emendo Biotherapeutics is a funded company, having raised a total of $61M across 1 funding round to date. The company's 1st funding round was a Series B of $61M, raised on Jan 2020.
Emendo Biotherapeutics was founded in 2015 in Ness Ziona, Israel, within the biotechnology sector. Protein engineering technology is utilized to re-design genome editing tools, including CRISPR-associated protein 9 (Cas9), transcription activator-like effector nucleases (TALENs), and zinc finger nucleases (ZFNs). These modifications aim to enhance homology-directed repair (HDR), minimize non-homologous end joining (NHEJ), boost specificity, and lower off-target effects for treating genetic disorders.
Emendo Biotherapeutics offers CRISPR Platform and Custom Nucleases.
Emendo Biotherapeutics has 2 investors. Key investors include AnGes, and Takeda Ventures.
Yes. Emendo Biotherapeutics was acquired by AnGes in December 2020.